



(12) Translation of
European patent specification

(11) NO/EP 2578231 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/395 (2006.01)
A61K 31/7068 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)
A61P 43/00 (2006.01)
C07K 16/28 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.01.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.10.26
(86)	European Application Nr.	11786748.1
(86)	European Filing Date	2011.05.27
(87)	The European Application's Publication Date	2013.04.10
(30)	Priority	2010.05.28, JP, 2010122951
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-ku Tokyo 115-8543, Japan National University Corporation Hokkaido University, Kita 8-jyo Nishi 5-chome Kita-ku Sapporo-shi, Hokkaido 060-0808, Japan
(72)	Inventor	NISHIMURA, Takashi, National University Corporation Hokkaido University Kita 8- jyo Nishi 5-chome Kita-ku, Sapporo-shi Hokkaido 060-0808, Japan
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	ANTITUMOR T CELL RESPONSE ENHANCER
(56)	References Cited:	EP-A1- 2 578 233 WO-A1-2009/148148 EP-A1- 2 305 306 JP-A- 2010 527 615 DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 August 2008 (2008-08-01), SEBBA ANTHONY: "Tocilizumab: the first interleukin-6- receptor inhibitor.", XP002713356, Database accession no. NLM18653811 & AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 1 AUG 2008, vol. 65, no. 15, 1 August 2008 (2008-08-01), pages 1413-1418, ISSN: 1535-2900 DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1992 (1992-02), AKIRA S ET AL: "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", XP002713357, Database accession no. NLM1643291 & SEMINARS IN CANCER BIOLOGY FEB 1992, vol. 3, no. 1, February 1992 (1992-02), pages 17- 26, ISSN: 1044-579X

DAI 68 KAI ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION 31 August 2009, page 286, XP008169109

Thomas R Ulich ET AL: "Intratracheal Injection of Endotoxin and Cytokines II. Interleukin-6 and Transforming Growth Factor Beta Inhibit Acute Inflammation", *American Journal of Pathology*, vol. 138, 1 May 1991 (1991-05-01), pages 1097-1101, XP055490383,

Sacchi A ET AL: "Treatment with monoclonal antibody to a Lewis lung carcinoma-associated antigen: different effects on primary tumor and its metastases", *Cancer Treat Rep.*, vol. 69, no. 9, 1 January 1985 (1985-01-01), pages 985-991, XP055784480,

OGATA TOSHIYUKI ET AL: "Early administration of IL-6RA does not prevent radiation-induced lung injury in mice", *RADIATION ONCOLOGY, BIOMED CENTRAL LTD, LO*, vol. 5, no. 1, 7 April 2010 (2010-04-07), page 26, XP021081382, ISSN: 1748-717X, DOI: 10.1186/1748-717X-5-26

Lancaster J.M. ET AL: "Identification of genes associated with ovarian cancer metastasis using microarray expression analysis", *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*, vol. 16, no. 5, 1 September 2006 (2006-09-01), pages 1733-1745, XP055784486, US ISSN: 1048-891X, DOI: 10.1111/j.1525-1438.2006.00660.x

ANDO KATSUTOSHI ET AL: "Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer", *PLOS ONE*, vol. 9, no. 7, 10 July 2014 (2014-07-10), page e102436, XP055784490, DOI: 10.1371/journal.pone.0102436

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1992 (1992-02), AKIRA S ET AL: "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", Database accession no. NLM1643291 & AKIRA S ET AL: "The evidence for interleukin-6 as an autocrine growth factor in malignancy.", *SEMINARS IN CANCER BIOLOGY FEB 1992*, vol. 3, no. 1, February 1992 (1992-02), pages 17-26, ISSN: 1044-579X

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 August 2008 (2008-08-01), SEBBA ANTHONY: "Tocilizumab: the first interleukin-6-receptor inhibitor.", Database accession no. NLM18653811 & SEBBA ANTHONY: "Tocilizumab: the first interleukin-6-receptor inhibitor.", *AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY : AJHP : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 01 AUG 2008*, vol. 65, no. 15, 1 August 2008 (2008-08-01), pages 1413-1418, ISSN: 1535-2900

J. VINCENT ET AL: "5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity", *CANCER RESEARCH*, vol. 70, no. 8, 15 April 2010 (2010-04-15), pages 3052-3061, XP055080069, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-3690

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 15 December 2007 (2007-12-15), DULUC DOROTHÉE ET AL: "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", XP002713350, Database accession no. NLM17848619 & *BLOOD 15 DEC 2007*, vol. 110, no. 13, 15 December 2007 (2007-12-15), pages 4319-4330, ISSN: 0006-4971

BECKER Y: "Molecular immunological approaches to biotherapy of human cancers - A review, hypothesis and implications", *ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR*, vol. 26, no. 2A, 1 March 2006 (2006-03-01), pages 1113-1134, XP008087034, ISSN: 0250-7005

PORGADOR ET AL: "INTERLEUKIN 6 GENE TRANSFECTION INTO LEWIS LUNG CARCINOMA TUMOR CELL SUPPRESSES THE MALIGNANT PHENOTYPE AND CONFERS IMMUNOTHERAPEUTIC COMPETENCE AGAINST PARENTAL METASTATIC CELLS", *CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US*, vol. 52, 1 July 1992 (1992-07-01), pages 3679-3686, XP002104479, ISSN: 0008-5472

TANAKA ET AL: "The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.", *CANCER RESEARCH*, vol. 57, no. 7, 1 April 1997 (1997-04-01), pages 1335-1343, XP055080260, ISSN: 0008-5472

ANNUAL REVIEW MEN'EKI vol. 1999, 1999, pages 257 - 269, XP008169107

SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY vol. 10TH, 2006, page 49, XP008168592

J.IMMNOL. vol. 154, no. 5, 1995, pages 2281 - 2290, XP055100942

SLEEMAN J ET AL: "Cancer metastasis as a therapeutic target", *EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL*, vol. 46, no. 7, 1 May 2010 (2010-05-01), pages 1177-1180, XP027027291, ISSN: 0959-8049 [retrieved on 2010-03-20]

TOSHIYUKI OGATA ET AL: "Anti-IL-6 receptor antibody does not ameliorate radiation pneumonia in mice", EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 4, no. 2, 1 August 2012 (2012-08-01), pages 273-276, XP055490373, GR ISSN: 1792-0981, DOI: 10.3892/etm.2012.582

LATULIPPE EVA ET AL: "Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, [Online] vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4499-4506, XP002507791, ISSN: 0008-5472

R Bellomo: "The cytokine network in the critically ill.", Anaesth Intensive Care, 20(3), 1 August 1992 (1992-08-01), pages 288-302, XP055490396, Retrieved from the Internet:

URL:<http://www.ncbi.nlm.nih.gov/pubmed/1524167> [retrieved on 2018-07-05]

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 15 December 2007 (2007-12-15), DULUC DOROTHÉE ET AL: "Tumor-associated

leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", Database accession no. NLM17848619 & DULUC DOROTHÉE ET AL: "Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.", BLOOD 15 DEC 2007, vol. 110, no. 13, 15 December 2007 (2007-12-15), pages 4319-4330, ISSN: 0006-4971

CHERYL A. ARMSTRONG ET AL: "Melanoma-Derived Interleukin 6 Inhibits In Vivo Melanoma Growth.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 102, no. 3, 1 March 1994 (1994-03-01), pages 278-284, XP055080261, ISSN: 0022-202X, DOI: 10.1111/1523-1747.ep12371782

ZANGARI MAURIZIO ET AL: "Immunomodulatory drugs in multiple myeloma.", EXPERT OPINION ON INVESTIGATIONAL DRUGS NOV 2005, vol. 14, no. 11, November 2005 (2005-11), pages 1411-1418, XP002713351, ISSN: 1744-7658

F. CABILLIC ET AL: "Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte?dendritic cell cross-talk", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 146, no. 3, 1 December 2006 (2006-12-01), pages 518-523, XP55080239, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2006.03212.x

E. SUZUKI: "Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity", CLINICAL CANCER RESEARCH, vol. 11, no. 18, 15 September 2005 (2005-09-15), pages 6713-6721, XP055080337, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-0883

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2005 (2005-11), ZANGARI MAURIZIO ET AL: "Immunomodulatory drugs in multiple myeloma.", Database accession no. NLM16255679 & ZANGARI MAURIZIO ET AL: "Immunomodulatory drugs in multiple myeloma.", EXPERT OPINION ON INVESTIGATIONAL DRUGS NOV 2005, vol. 14, no. 11, November 2005 (2005-11), pages 1411-1418, ISSN: 1744-7658

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** Sammensetning for anvendelse i behandling av kreft ved å forsterke en antitumor T-cellerespons i en tumorbærende organisme, som omfatter et anti-interleukin 6 (IL-6) reseptor antistoff og videre omfatter gemcitabin eller salt derav, hvori nevnte tumorbærende organisme er et pattedyr, og hvor behandlingen av kreft resulterer i en reduksjon i tumorvevsvolum.
- 2.** Sammensetning for anvendelse ifølge krav 1, hvori anti-IL-6-reseptorantistoffet er et kimært, humanisert eller humant antistoff.
- 3.** Sammensetning for anvendelse ifølge krav 1 til 2, hvori gemcitabinet eller saltet derav er gemcitabinhydroklorid.
- 4.** Sammensetning for anvendelse ifølge hvilket som helst av kravene 1 til 3, hvori pattedyret er et menneske.